Midazolam

Clinical contraindication: None listed; No clinical contraindication identified.
Best available evidence: Standard practice
Half-life: 1.8–6.4 h; Approximate, in adults. Detail in 01.

Named in state rules?

CONot named

ORNot named

NMPending

Cite asPsilodex: midazolam · v2026.10.02

Clinical data and state rules are separate facts. Both are shown; neither is a decision.

01 Interaction with psilocybin

Blunting and sedation if present; may appear as a seizure-rescue medication.

Human data with psilocybin: None known: no published human data with psilocybin
Common practice: Daily use carries withdrawal risk if stopped abruptly. Any change is the prescriber's decision.
Half-life: 1.8–6.4 h (FDA label, checked 2026-09-30)

Evidence types on this record

PrStandard practice; no psilocybin-specific data

02 Pharmacology relevant to psilocybin

1 listed · counted on reports

Sedating or CNS depressant: Slows the central nervous system: drowsiness, slower reactions and impaired coordination, and slowed breathing at high doses. Effects add with other sedating substances. Sources [1]

03 State rules

Official text governs

CO4 CCR 755-1

Not named

No provision names this medication or its class.

Colorado · checked 2026-09-30

OROAR 333-333

Not named

No provision names this medication or its class.

Oregon · checked 2026-09-30

NM7.35.3 NMAC (proposed)

Pending

New Mexico's clinical rules (proposed 7.35.3 NMAC) are not final. No provision naming this medication has been found.

New Mexico · checked 2026-09-30

04 Conditions to ask about

Screening items in state rules

This medication is usually taken for a condition. State rules screen for some conditions directly, so the medication is a prompt to ask about them. Confirm with the participant; never assume a condition from the medication.

Seizure disorder (possible indication)CO 2.5(A)(2)

05 Sources

Midazolam Injection, USP · FDA label (DailyMed)

Report an error in this record →